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Gregory L. Moneta, MD, Section EditorEndoscopic Lumbar Sympathectomy for Plantar Hyperhidrosis
Rieger R, Pedevilla S, Pöchlauer S. Brit J Surg 2009;96:1422-8.
Conclusion: In patients with severe plantar hyperhidrosis, endovascu-
lar lumbar sympathectomy is safe and effective.
Summary: Primary plantar hyperhidrosis is characterized by excessive
secretion by eccrine sweat glands of the feet. The etiology is unknown and
symptoms include cold cyanotic skin, skin maceration, bacterial and fungal
infection, and bromidrosis (foul-smelling feet). Interrupting innervation of
the sweat glands stops sweat secretion and has been used since the 1920’s to
treat hyperhidrosis. Whereas lumbar sympathectomy has been used to treat
plantar hyperhidrosis, use of this operation for this condition is relatively
infrequent. The authors’ present data regarding potential benefit of lumbar
sympathectomy in patients with plantar hyperhidrosis treated with an endo-
scopic approach. Ninety patients had 178 endoscopic resections of lower
sympathetic lumbar trunks for an indication of severe plantar hyperhidrosis.
There were 59 men and 31 women. Mean follow up was 24 (range, 3-45)
months. There were no perioperative deaths. Only three patients had post
operative complications.
The procedure is performed under general anesthesia with the patient
in a hyper-extended flank position. Projection of lumbar vertebral bodies on
the anterior abdominal wall was marked fluoroscopically. Retroperitoneos-
copy was performed using three trocars with continuous carbon dioxide
insufflations. The lumbar sympathetic trunk is exposed at the level of third
and fourth lumbar vertebral bodies. Metal clips are placed above and below
transaction sites and the sympathetic trunk resected between the clips, along
with ganglia for L3 and/or L4. Evidence of postoperative sympathetic
deintervention of the feet was present in all patients. In 97% (n  87),
hyperhidrosis was eliminated. It recurred in 3%. Postsympathetic neuralgia
occurred in 42% and compensatory sweating in 42%. One patient had
temporary loss of ejaculation. Ninety-six percent said they were very or partly
satisfied and 92% would have the procedure repeated if required.
Comment: Conservative treatment of hyperhidrosis can improve
symptoms. However, it is usually ineffective in severe cases and certainly does
not affect long term outcome of the disease. Complications of postsympa-
thetic neuralgia and compensatory sweating were both frequent in this
series. Postsympathetic neuralgia however was minor and temporary and
only one patient had severe compensatory sweating. Permanent sexual
dysfunction appears unlikely as long as sympathectomy is below the level of
third or fourth lumbar vertebral body. The technique appears to be reason-
able treatment for patients with severe plantar hyperhidrosis.
Endovascular versus Open Repair of Abdominal Aortic Aneurysm
The United Kingdom EVAR Trial Investigators. New Engl J Med 2010;
362:1863-71.
Conclusion: Endovascular repair of abdominal aortic aneurysm (AAA)
has lower operative mortality than open repair. There is no difference in
aneurysm-related or total mortality in the long term. There are increased
rates of graft complications with endovascular repair, more reinterventions,
and endovascular repair is more costly.
Summary: Lower 30-day operative mortality with endovascular versus
open surgical repair of AAA has been demonstrated in three large random-
ized trials (Lancet 364:843-8, N Engl J Med 2004;351:1607-18, and JAMA
2009;309:1535-42). Open abdominal aneurysm repair appears durable
(JVS 1997;25:277-84 and JVS 2007;46:669-75). However, little long-term
follow-up of endovascular repair is available. The EUROSTAR registry
provides registry data for a mean follow-up of only three years and
incorporates many endografts no longer in current use (Arch Surg
2007;142:33-41).
This report from the United Kingdom EVAR investigators presents
long-term follow-up data of the EVAR 1 trial. In EVAR 1, from 1999
through 2004, there were 1252 patients with AAAs 5.5 cm who were
randomly allocated to undergo either endovascular or open repair at 37
hospitals in the United Kingdom. There were 626 patients in each group.
Resource use, graft-related complication, reinterventions, and rates of death
were then determined until the end of 2009. In the endovascular repair
group and open repair group, 30-day operative mortalities were 1.8% and
4.3%, respectively (adjusted odds ratio for endovascular repair compared to
open- epair, 0.39; 95% CI, 0.18 to 0.87; P  .02). Early benefit of
endovascular repair with respect to aneurysm-related mortality was lost by
the end of the study, at least partially, because of fatal endograft ruptures
(adjusted hazard ratio, 0.92; 95% CI, 0.57 to 1.49; P .73). No significant
difference between the two groups in the rate of death from any cause was
present by the end of follow-up (adjusted hazard ratio, 1.03; 95% CI, 0.86
252to 1.23; P .72). There were higher rates of graft-related complications and
reinterventions with endovascular repair. New complications occurred up to
8 years following randomization, contributing to overall higher cost of
endovascular repair.
Comment: The value of the study is the long-term prospective nature
of the data and excellent follow-up with very few patients lost to follow-up.
The results of the study, in general, are not surprising in that they confirm
previously published midterm findings of the EVAR 1 trial and other trials
evaluating endovascular vs open repair of AAAs. Operative mortality with
endovascular AAA repair is significantly lower than with open AAA repair
and aneurysm-related mortality is reduced early on. Early benefit, however,
is “completely lost in the longer-term” with no differences in long-term
mortality and higher aneurysm-related mortality after 4 years in the
patients treated with EVAR. The authors note secondary rupture after AAA
repair was associated only with EVAR and “appeared” to explain the late
aneurysm-related mortality in the EVAR patients. These data indicate EVAR
for AAA is not as big a win for patients in the long-term as was hoped and,
with the current cost structure, is clearly a loss for the economics of health
care system.
Endovascular Repair of Aortic Aneurysm in Patients Physically Ineli-
gible for Open Repair
The United Kingdom EVAR Trial Investigators. New Engl J Med 2010;
362:1872-80.
Conclusion: In patients ineligible for open repair, endovascular repair
of abdominal aortic aneurysm (AAA) is associated with a lower rate of
aneurysm-related mortality than no repair. Endovascular repair, however, is
not associated with a reduction in the rate of death from any cause. Rate of
graft-related complications and reinterventions were high and contributed
to increased cost.
Summary: An early premise of endovascular repair of AAA was that it
would be used in patients ineligible for open surgical repair with the
expectation that life would be prolonged by eliminating the risk of fatal
aneurysm rupture. Midterm results of EVAR 2 showed no benefit of
endovascular repair on total or aneurysm-related mortality up to 4 years of
follow-up (Lancet 2005;365:2187-92). In EVAR 2, operative mortality was
higher than anticipated (9%) and there was a 68% mortality at 4 years. In
addition, belated rupture of large, untreated aneurysms was lower than
anticipated (9 ruptures per 100 person-years). The current study was de-
signed to test the hypothesis that the benefits of endovascular repair may take
longer than four years to become apparent.
In EVAR 2, 404 patients with AAAs 5.5 cm in diameter and consid-
ered ineligible for open repair were randomized to either undergo endovas-
cular repair or no repair. The study was conducted in 33 hospitals in the
United Kingdom from 1999 through 2004. The endovascular repair group
consisted of 197 patients, and 207 were assigned to no intervention. Until
the end of 2009, patients were followed for graft related complications,
reinterventions, and rates of death.
The endovascular repair group 30-day operative mortality was 7.3%.
Overall rate of AAA rupture in the no intervention group was 12.4 per 100
person-years (95% CI, 9.6 to 16.2). There was lower AAA-related mortality
in the endovascular repair group (adjusted hazard ratio, 0.53; 95% CI, 0.32
to 0.89; P  .02). However, the advantage of decreased AAA-related
mortality did not result in any benefit of total mortality (adjusted hazard
ratio, 0.99; 95% CI, 0.78 to 1.27; P  .97). Of patients surviving endovas-
cular repair, 48% had graft-related complications. Within the first 6 years,
27% required reintervention. Over the 8 years of follow up, endovascular
repair was considerably more expensive than no repair (cost difference, U.S.
$ 14,867; 95% CI, 11,556 to 18, 176).
Comment: The midterm results of the EVAR 2 reported in 2005 did
not support endovascular repair of AAAs in patients considered unfit for
open repair. Now, with longer follow-up, the authors report benefit of
endovascular repair in terms of aneurysm-related mortality but not in long
term all-cause mortality. Patients in the study had a limited life expectancy,
regardless of whether the aneurysm was managed with EVAR or no inter-
vention was performed. There were few survivors beyond 8 years in either
group. Many patients in the no intervention group crossed over to EVAR
and these patients were, on post hoc analysis, found to be more “fit” than
those that did not cross over. There were only two late ruptures in the EVAR
group; perhaps related to the limited survival of the patients in general. One
conclusion is the patients did not survive long enough to die of rupture
following EVAR. Looking at both the late results of EVAR 1 and EVAR 2,
one might conclude poor risk patients can, in terms of aneurysm related
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best managed with open repair.
Growth Rate of Affected Aorta in Patients with Type B Partially Closed
Aortic Dissection
Sueyoshi E, Sakamoto I, Uetani M. Ann Thorac Surg 2009;88:1251-7.
Conclusion: In patients with type B aortic dissection, entirely patent
false lumens have higher growth rates than partially-patent false lumens.
Completely-occluded false lumens have the lowest false lumen growth rate.
Summary: Studies of patients with Type B aortic dissection have
suggested those with complete thrombosis of the false lumen have improved
outcomes compared to those where the false lumen remains patent with such
patients having an increased risk of aortic enlargement and death (Am J Card
2001;87:1378-82 and Lancet 1997;349:1461-4). A recent study suggested
stratification of patients with patent false lumens into those where the false
lumen is partially-patent with nonoccluding thrombus and those with a
patent false lumen without associated thrombus. That study found an
increased risk of death in the patients with partial thrombosis of the false
lumen (N Engl J Med 2007;357:349-59). This later study did not describe
the natural history of the affected aorta or the cause of death in patients with
partially-closed false lumens.
In the current study, the authors evaluated the evolution of the
dissected aorta and the growth rate of Type B aortic dissections using
computed tomography scanning. Patients were divided into 4 groups.
Group A consisted of those with completely-closed false lumens. Group B
consisted of patients with a patent false lumen with continuous blood flow
from entry to reentry without regard to presence of thrombus in the false
lumen. Group C consisted of patients with partially-closed false lumens
defined as a false lumen partially-closed by a thrombus in any part of the false
lumen. Group D was a subset of group C when the partially-closed false
lumen was in the distal portion of the false lumen with the proximal potion
of the false lumen patent. The mean fastest growth rates for patients with
completely closed false lumens, partially-closed false lumens, and patent false
lumens were 0.2  0.6, 4.0  4.3, and 4.9  4.5 mm/year, respectively.
Differences were statistically significant (P  .0149). Among the group C
patients, there were only 3 Group D patients with the growth rates of the
Group D vs Group C patients being 12.7  1.1 and 2.6  2.7 mm/year
respectively, P  .007.
Comment: The article suggests a discrepancy between causes of death
and the natural history of the aorta in patients with completely patent versus
partially-patent false lumens following Type B aortic dissection. The current
study indicates the natural history of a false lumen that is completely patent
appears worse, in terms of growth rates, than the partially-patent false lumen.
Certainly it would be useful to know whether the partially-patent false lumen
versus the completely-patent false lumen has a higher risk of rupture. The
walls of the dissected aorta with partially-patent false lumens may have a
combination of diminished strength and relative hypoxia of the arterial wall
adjacent to the internal luminal thrombus that results in increased local
inflammation and wall weakening (JVS 1994;20:529-35 and Circulation
2005;111:1063-71). The implication is there may be factors other than
simple expansion of the luminal diameter that predispose to rupture of the
false lumen in patients with Type B aortic dissection.
Incidence of Moderate to Severe Cognitive Dysfunction in Patients
Treated with Carotid Artery Stenting
Gaudet JG, Meyers PM, McKinsey JF, et al. Neurosurgery 2009;65:325-30.
Conclusion: Carotid artery stenting is associated with cognitive per-
formance decline of modern severity one day after stenting.
Summary: Neuropsychometric test are not routinely used to evaluate
the effects of carotid interventions. Comparison of primary cognitive dys-
function in patients undergoing carotid endarterectomy (CEA) versus those
undergoing carotid artery stenting (CAS) suggests patients treated with CAS
tend to perform slightly worse with selective cognitive tests. There is,
however, little prospective information on cognitive function using controls
subjects, those not undergoing a cerebrovascular intervention. In this pro-
spective, observational study, they compared the incidence of early cognitive
dysfunction in patients undergoing CAS with embolic protection devices
using a control population consisting of patients undergoing percutaneous
coronary artery procedures.
There were 24 patients who underwent elective CAS and 23 patients
who underwent a coronary procedure. Coronary procedures were all
catheter-based and performed by members of the interventional cardiology
service. All CAS procedures were performed by either the Neurovascular
service or the vascular surgical service at the authors’ institution. Subjects
underwent a battery of six neuropsychometric tests chosen to represent a
range of cognitive demands. Mean changes and standard deviations for
patients undergoing coronary stenting procedures were used to calculate Z
scores for each test. A negative value indicated a cognitive performance
worse than that of the mean of controls. Negative Z scores were then
transformed into injury points for each neuropsychometric test. An averagedeficit score (ADS) was calculated by dividing the sum of injury points by the
total number of completed tests. Patients were considered to have moderate
to severe cognitive dysfunction if their ADS was greater than the control
mean by a minimum of 1.5 standard deviations and/or Z scores of 1.5 on
2 or more tests. Severe cognitive dysfunction was defined as ADS greater
than the control mean by a minimum of 2 standard deviations and/or Z
scores of  2 on 2 or more tests.
The controlled patients tend to be younger and had a lower incidence
of stroke or previous transient ischemic attack. On the first day after surgery,
41% of patients treated with CAS developed moderate to severe cognitive
dysfunction (P .0422). Average deficit scores were also significantly higher
in the CAS group at one day (P .0265). Differences were independent of
history of stroke, transient ischemic attack, or age. At one month, one of 11
patients assessed (9%) who had been treated with CAS still exhibited
cognitive dysfunction.
Comment: The effect of carotid interventions on cognitive function is
an area of research that needs more long-term data. It would also be very
interesting to correlate cognitive function with postprocedure MRI diffu-
sion weighted imaging (DWI) studies. At this point we really don’t know
whether DWI lesions have any actual short-term or long-term effects. We do
know, however, that DWI lesions are considerably more common after CAS
than CEA. This paper is of value primarily to bring this line of quantitative
cognitive research to our attention and in demonstrating the techniques
used to generate the information.
Mortality and Vascular Morbidity in Older Adults with Asymptomatic
Versus Symptomatic Peripheral Artery Disease
Diehm C, Allenber JR, Pittrow D, et al, for the German Epidemiological Trial
on Ankle Brachial Index Study Group. Circularion 2009;120:2053-61.
Conclusion: In patients with peripheral arterial disease (PAD), the risk
of mortality is similar in those patients where PAD is symptomatic and in
those patients where it is asymptomatic. In both groups, mortality is higher
than in those without PAD.
Summary: PAD is widespread, especially in elderly patients and those
with diabetes mellitus or with clusters of cardiovascular risk factors. PAD is
known to be associated with increased risk of premature mortality and
cardiovascular and cerebrovascular events (Circulation 2006;114:688-99).
Studies regarding relative mortality of patients with symptomatic versus
asymptomatic PAD are a bit conflicting. One described progressive increase
in mortality as patients moved from asymptomatic to symptomatic or
severely symptomatic status (N Engl J Med 1992;326:381-86). Another
study demonstrated asymptomatic PAD patients had higher rates of morbid
events than symptomatic patients (Intern J Epid 1996;25:1172-81). An-
other study indicated patients with asymptomatic PAD have poorer quality
of life and functional performance than patients with intermittent claudica-
tion (Circulation 2008;117:2484-91). The authors, therefore, thought to
describe in a German population the prevalence of asymptomatic and
symptomatic PAD and to relate symptomatic status to clinical events.
The patients are part of the German Epidemiologic Trial on Ankle
Brachial Index (getABI). This is an ongoing, prospective, observational,
cohort study that began in October 2001. Three hundred forty-four general
practice physicians in Germany were trained in identification of patients with
PAD. Patients were then identified in their practices during a prespecified
week in October 2001. Approximately 20 eligible patients per practice met
the inclusion criterion (age  65 years, legally competent, and able to
cooperate appropriately and provide consent with life expectancy  6
months). ABIs were determined and patients were followed under a stan-
dardized protocol for development of cardiovascular events. There were
6880 patients followed for over 5 years. Of these, 5392 were felt to have no
PAD. There were 836 who were felt to have asymptomatic PAD (ABI 0.9
without symptoms). A total of 593 were felt to have symptomatic PAD
(lower extremity revascularization, amputation secondary to PAD, or symp-
toms consistent with intermittent claudication regardless of ankle brachial
index).
For the composite endpoint of all-cause death or severe vascular event
(myocardial infarction, stroke, carotid revascularization, coronary revascu-
larization, lower extremity peripheral vascular events) risk was increased in
patients with symptomatic compared to asymptomatic PAD (HR, 1.48; 95%
CI, 1.21 to 1.80). There were no differences between patients with symp-
tomatic and asymptomatic PAD for all-cause death alone (HR, 1.13; 95%
CI, 0.89 to 1.43), all-cause death/myocardial infarction/stroke (HR, 1.18;
95% CI, 0.92 to 1.52), or for cardiovascular events alone (HR, 1.20; 95% CI,
0.89 to 1.60), or cerebrovascular events alone (HR, 1.33; 95% CI, 0.80 to
2.20). Risk was increased in lower ABI categories.
Comment: Overall, in the primary practice setting, there was a high
prevalence of PAD (12.2% asymptomatic, 8.7% symptomatic). The compos-
ite end point of all-cause mortality or severe cardiac cerebral or peripheral
vascular events occurred in 104.7 cases per 1000 patient years in patients
with symptomatic PAD, 60.4 cases per 1000 patient years in patients with
asymptomatic PAD, and in 27.2 cases per 1000 patient years in patients
without PAD. However, for the individual end points of all-cause death
alone, all-cause death/myocardial infarction/stroke, and for cardiovascular
